000 01334 a2200373 4500
005 20250517165153.0
264 0 _c20171026
008 201710s 0 0 eng d
022 _a1759-4782
024 7 _a10.1038/nrclinonc.2017.96
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGingras, Isabelle
245 0 0 _aHER2-positive breast cancer is lost in translation: time for patient-centered research.
_h[electronic resource]
260 _bNature reviews. Clinical oncology
_cNov 2017
300 _a669-681 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aBiomarkers, Tumor
_xgenetics
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aChemotherapy, Adjuvant
650 0 4 _aClinical Trials as Topic
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aNeoadjuvant Therapy
650 0 4 _aPrecision Medicine
_xmethods
650 0 4 _aReceptor, ErbB-2
_xgenetics
650 0 4 _aSignal Transduction
650 0 4 _aTranslational Research, Biomedical
650 0 4 _aTreatment Outcome
700 1 _aGebhart, Géraldine
700 1 _ade Azambuja, Evandro
700 1 _aPiccart-Gebhart, Martine
773 0 _tNature reviews. Clinical oncology
_gvol. 14
_gno. 11
_gp. 669-681
856 4 0 _uhttps://doi.org/10.1038/nrclinonc.2017.96
_zAvailable from publisher's website
999 _c27420817
_d27420817